ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Addex Pharma S.A.

Criteria

Inclusion Criteria:

• diagnosis of typical GERD

• well controlled on a standard clinical symptoms controlled dose of PPI treatment

• body mass index ≤32 kg/m2

Exclusion Criteria:

• exclusively atypical symptoms of GERD

• symptoms that have been shown not to be associated with GERD

• erosive oesophagitis

• hiatus hernia > 3 cm

• current diagnosis of co-existing psychiatric disease

• known clinically significant allergy or known hypersensitivity to drugs

• pregnant or breast-feeding

• has received sodium valproate or topiramate within 30 days of Screening

• has a history of a significant medical condition that may affect the safety of the patient or preclude adequate participation in the study